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Abstract
Background: Observational clinical studies have shown that patients with diabetes have less
favorable results after percutaneous coronary intervention compared with the non-diabetic
counterparts, but its mechanism remains unclear. The aim of this study was to examine the changes
of neointimal hyperplasia after sirolimus-eluting stent (SES) implantation in a diabetic porcine
model, and to evaluate the impact of aortic inflammation on this proliferative process.
Methods: Diabetic porcine model was created with an intravenous administration of a single dose
of streptozotocin in 15 Chinese Guizhou minipigs (diabetic group); each of them received 2 SES
(Firebird, Microport Co, China) implanted into 2 separated major epicardial coronary arteries.
Fifteen non-diabetic minipigs with SES implantatio n  s e r v e d  a s  c o n t r o l s  ( c o n t r o l  g r o u p ) .  A t  6
months, the degree of neointimal hyperplasia was determined by repeat coronary angiography,
intravascular ultrasound (IVUS) and histological examination. Tumor necrosis factor (TNF)-α
protein level in the aortic intima was evaluated by Western blotting, and TNF-α, interleukin (IL)-
1β and IL-6 mRNA levels were assayed by reverse transcription and polymerase chain reaction.
Results: The distribution of stented vessels, diameter of reference vessels, and post-procedural
minimal lumen diameter were comparable between the two groups. At 6-month follow-up, the
degree of in-stent restenosis (40.4 ± 24.0% vs. 20.2 ± 17.7%, p < 0.05), late lumen loss (0.33 ± 0.19
mm vs. 0.10 ± 0.09 mm, p < 0.001) by quantitative angiography, percentage of intimal hyperplasia
in the stented area (26.7 ± 19.2% vs. 7.3 ± 6.1%, p < 0.001) by IVUS, and neointimal area (1.59 ±
0.76 mm2 vs. 0.41 ± 0.18 mm2, p < 0.05) by histological examination were significantly exacerbated
in the diabetic group than those in the controls. Significant increases in TNF-α protein and TNF-α,
IL-1β and IL-6 mRNA levels were observed in aortic intima in the diabetic group.
Conclusion: Neointimal hyperplasia persisted at least up to 6 months after SES implantation in
diabetic porcine, which may be partly related to an exaggerated inflammatory response within the
blood vessel wall. Our results provide theoretical support for potential direct beneficial effects of
anti-diabetic and anti-inflammation medications in reducing the risk of restenosis after stenting.
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Background
Diabetes mellitus has now been a worldwide epidemic
and is growing as a public problem. Coronary artery dis-
ease is highly prevalent and becomes the major cause of
morbidity and mortality in diabetic patients [1-4]. Mean-
while, approximately 25% of patients undergoing percu-
taneous coronary intervention have diabetes [5,6], and
diabetes has been repeatedly identified as an independent
predictor of restenosis after coronary balloon angioplasty
or bare-metal stent implantation [7]. The advent and clin-
ical application of drug-eluting stents have been regarded
as the third milestone in interventional cardiology.
Numerous animal experiments and clinical trials have
demonstrated the safety and efficacy of sirolimu-eluting
stents (SES) in treating patients with coronary artery dis-
ease, by dramatically inhibiting neointimal hyperplasia
and reducing incidence of in-stent restenosis and conse-
quently target lesion revascularization, as comparing to
the bare-metal stents [8,9]. However, the beneficial effects
of SES remain less favorable for diabetic patients than for
their non-diabetic counterparts [10,11], and repeat revas-
cularization in diabetic patients continues to be substan-
tially higher [5,12]. The high risk features of diabetic
patients with coronary artery disease may include hyperg-
lycemia, insulin resistance, dyslipidemia, inflammation,
and thrombophilia [13,14]. The interaction between dia-
betes and coronary disease is intricate and still needs to be
elucidated and focused by both clinicians and basic
researchers. Animal models were widely used in diabetes
research, but most experiments were done on rodents for
various purposes [15]. Large animal models may be more
reliable to reflect the clinical status of diabetes, due to
their resemblance to human diabetes and diabetic com-
plications in physiology and pathophysiology [16]. In this
study, we tested the concept that vascular response was
exaggerated in diabetic porcine even after implantation of
drug-eluting stents, and activation of cytokines in the
blood vessel wall was involved in sustaining proinflam-
matory mechanisms leading to neointimal proliferation.
Methods
Establishment of diabetic model
Fifteen juvenile Chinese Guizhou minipigs (male, aged
mean 5 months) obtained from Shanghai Jiaotong Uni-
versity Agriculture College, were raised in separated pens
under controlled conditions in the Department of Animal
for Scientific Research, Jiaotong University School of Med-
icine. All minipigs had normal day-night cycle, and room
temperature was kept between 18 to 25°C with continu-
ous air changing. Diabetic model was made using intrave-
nous injection of streptozotocin (STZ) by the method
described previously [16,17]. Briefly, STZ (S0130, Sigma)
was administrated intravenously through an indwelling
catheter at a dose of 125 mg/kg after dissolving in sodium
citrate buffer (pH 4.7). Elevated blood glucose levels were
always observed at the third or fourth day after STZ
administration using one-touch SureStepPlus instrument
(Johnson & Johnson Inc. USA). Insulin therapy was initi-
ated, if necessary, to maintain a fasting glucose level
below 10 mmol/l [18]. Novolin@ 30R (Novo Nordisk,
Denmark) was given subcutaneously in 14 (93.3%) ani-
mals with an average dose of 6.8 ± 2.6 U in the morning
and 4.5 ± 1.6 U in the afternoon before meals.
Another 15 age-matched male minipigs without diabetes
served as controls (control group). The fasting blood glu-
cose level and body weight at baseline were similar. At 6
months, diabetic animals had significantly lower body
weight and increased fasting blood glucose level even after
exogenous insulin treatment [18].
Intracoronary stenting and IVUS imaging
Coronary angiography and stent implantation were per-
formed after stabilizing blood glucose level in diabetic
group (mean 12 ± 4 days after STZ administration). Aspi-
rin (Bayer, 300 mg/d) and ticlopidine (Sanofi-Aventis,
250 mg/d) were given at least 2 days before catheter pro-
cedures. All animals were sedated with intramuscular ket-
amine hydrochloride (20 mg/kg) and midazolam (1 mg/
kg). After tracheal intubation, anesthesia was induced
with mechanical ventilation of oxygen and isoflurane.
Right femoral artery was exposed, a 6F arterial sheath was
inserted and 200 IU/kg heparin was given via the sheath
immediately. A 6F Amplatz right coronary guiding cathe-
ter (Cordis, USA) was usually used to engage both right
and left coronary arteries. For each animal, 2 Firebird SES
(Microport Co, Shanghai, China) with 18 mm in length
and 2.5 mm or 3.0 mm in diameter according to the size
of reference vessels were implanted with the stent-to-ves-
sel ratio of 1.1~ 1.2:1 [19]. The stent was polymer-based
and coated with sirolimus (9 µg/mm), and its efficacy and
safety in inhibiting neointimal hyperplasia have been
demonstrated by animal experiments and clinical studies
[8,20]. After procedure, the accessed femoral artery was
ligated, and the animal was extratubated once spontane-
ous respiratory recovery occurred. Continuous electrocar-
diographic and blood pressure monitoring was made
during the procedure. Aspirin and ticlopidine were con-
tinued to the end of study in all animals.
Repeat angiography was performed at 6 months through
the counterlateral femoral artery. Meticulous care was
taken to obtain coronary angiography at similar projec-
tions, as possible. Intravascular ultrasound (IVUS) imag-
ing was made to evaluate the degree of neointimal
hyperplasia in all stented vessels. All IVUS images were
acquired with automated pullback at 0.5 mm/s after intra-
coronary nitrates using a commercially available imaging
system (Galaxy II, Boston Scientific).Cardiovascular Diabetology 2007, 6:16 http://www.cardiab.com/content/6/1/16
Page 3 of 7
(page number not for citation purposes)
Image analysis
Offline quantitative analysis of procedural, post-proce-
dural, and 6-month follow-up angiography was per-
formed by an independent core laboratory (TERRA, GE,
USA). All imaging analyses included the stented segment
as well as their margins, 5 mm proximal and distal to the
stent. Late lumen loss was defined as the difference
between the minimal lumen diameter immediately after
procedure and at 6 months. Restenosis was defined as a
reduction of 50% or more of the lumen diameter.
Volumetric IVUS analysis was made with the commer-
cially available software (VIVI Viewer 1.6, Beijing JX Dig-
ital Wave Co.) according to protocols previously validated
[21]. In brief, vessel, stent, lumen, and neointimal vol-
umes were computed for the stented segment as well as its
margins 5 mm distal and proximal to the stent. Percentage
of intimal hyperplasia was defined as neointimal volume
divided by stent volume.
Histological assessment
After completion of follow-up angiography and IVUS
imaging, an additional dose of 10000 IU heparin was
given, and all animals were then euthanized and the
hearts were excised. Meticulous care was taken to isolate
stented coronary segment (including at least 10 mm of
both ends), and the stented coronary vessel was processed
according to the standard method described previously
[22]. The final vessel sections were stained with hematox-
ylin eosin. Lumen area, area within the internal elastic
lamina (IEL) and maximal intimal thickness were com-
puted (Leica-Qwin software) under the microscope
(Olympus-AH2). Neointimal area was determined by IEL
minus lumen area. Corrected percentage of stenosis was
obtained by dividing percent stenosis by injury score (IS),
which was evaluated as: 0 = strut in intima but not in con-
tact with IEL; 1 = strut in contact with but not penetrating
IEL; 2 = strut penetrating IEL, in contact with media but
not contacting external elastic lamina (EEL); 3 = strut con-
tacting but not penetrating EEL; and 4 = strut penetrating
EEL and in contact with adventitia [23].
Determination of inflammatory factors
Secretary proteins in aortic intima conditioned medium
were examined for TNF-α expression by Western blotting
in order to investigate inflammatory status, because anti-
human TNF-α antibody worked on porcine TNF-α. The
levels of TNF-α, IL-1β and IL-6 mRNA in aortic intima
were evaluated using reverse transcription and polymer-
ase chain reaction (RT-PCR). Briefly, total RNA of aortic
intima was extracted using kits (Qiagen, USA) and then
quantified. RT-PCR for TNF-α, IL-1β and IL-6 mRNA
amplification was performed with primes (Table 1).
Cytokine mRNA levels were analyzed by normalizing with
GAPDH mRNA expression. Incubation of tissue explants
(aortic intima) in RPMI medium with 1% PSA and 2%
HEPES supplement was made under sterile conditions
(37°C, 5% CO2) for 24 hours. The proteins in condi-
tioned medium were quantified and subjected to SDS-
PAGE, and transferred to a polyvinylidene difluoride
membrane (Millipore, USA). Equal loading was verified
with Ponceau Red staining on the membranes following
protein transfer. The membrane was incubated with anti-
body against porcine TNF-α (sc-8301, Santa Cruz, USA)
and immunodetection was performed using ECL Western
blotting detection reagents (Amersham Biosciences,
USA).
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
Comparisons between groups were made by student t test
or ANOVA when appropriate. SPSS for Windows 13.0
(SPSS Inc., Chicago, Illinois) software was used for statis-
tical analysis. A value of p < 0.05 was considered signifi-
cant for evaluating difference between the two groups.
Results
Procedural characteristics
Two animals in diabetic group and one in control group
developed ventricular fibrillation during stent implanta-
tion, which was successfully resuscitated by direct electri-
cal shock. All stents were successfully deployed into the
coronary vessels. The distribution of stented vessels and
reference vessel diameter prior to the procedure and min-
imal lumen diameter immediately post stenting were sim-
ilar in the two groups (Table 2, all P > 0.05). During
follow-up, 2 animals experienced pulmonary infection
which was treated successfully with intramuscular antibi-
otics (Penicillin) administration, and all survived to the
end of the study.
Angiographic and IVUS features
At 6-month follow-up, overall in-stent restenosis rate was
higher in the diabetic group, but did not reach statistical
significance level compared to control group (23.3% vs.
6.7%, p = 0.15). Angiographic minimal lumen diameter
of the stented segment was significantly smaller in dia-
betic group than in control group, as well as percentage of
intimal hyperplasia at IVUS analysis, resulting in signifi-
cantly increased late lumen loss in diabetic group (Table
3). No significant differences were observed of angio-
graphic and IVUS measurements between the left and
Table 1: Primers for TNF-α, IL-1β and IL-6 mRNA amplification
Target gene Forward primer (5'-3') Reverse primer(5'-3')
TNF-α ggctgtacctcatctactcc cagcaaagtccagatagtcg
IL-1β gatgaggagtatgagagcga gacaggcttatgttctgcttg
IL-6 gtgagaagtatgagaagtgtga gcaggatgagaatgatctttg
GAPDH acgaccatggagaaggctg tcgtacgaggaaatgagctCardiovascular Diabetology 2007, 6:16 http://www.cardiab.com/content/6/1/16
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right coronary system in diabetic and control animals,
and no stent- related thrombosis formation was found in
both groups.
Histological findings
The degree of intimal injury caused by stent deployment
was similar between the two groups. Significantly aggra-
vated intima hyperplasia was observed in diabetic group
by morphometric analysis with parameters of percentage
of stenosis, intima area, medial area and maximal intimal
thickness (Table 4). The photomicrograph of the intimal
proliferative response to stent implantation in the dia-
betic and control groups was shown in Figure 1A and 1B.
Uncorrected and corrected percentage of stenosis between
the two groups was displayed in Figure 2.
Inflammatory cytokines in aortic wall
Compared to controls, dramatic elevation in TNF-α levels
was revealed in aortic intima of diabetic group (p < 0.001,
Fig. 3). The result was supported by immunohistochemi-
cal assessment, which displayed more TNF-α expression
in diabetic porcine aorta (Fig. 3). RT-PCR examination
demonstrated significantly higher levels of TNF-α, IL-1β
and IL-6 mRNA in aortic intima of diabetic porcine, as
comparing to the controls (Fig. 4), which was also parallel
to the results of Western blotting.
Discussion
The current study indicates that diabetic state attenuated
the anti-proliferation effects of SES as comparing to the
non-diabetic counterpart. Angiographic and IVUS follow-
up at 6 months, as well as histological examinations after
animal sacrifice demonstrated a significant increase in late
lumen loss and reduction of lumen area caused by exacer-
bated neointimal hyperplasia after coronary stenting in
the diabetic porcine. An exaggerated inflammatory
response within the aortic wall of the diabetic model was
proved by Western blotting and RT-PCR, similar to the
results previously reported [18]. Enhanced expression of
proinflammatory mediators in diabetic vasculature may
be linked to multiple mechanisms germane to progres-
sion of in-stent restenosis, such as smooth muscle cell
migration and arterial remodeling.
Coronary restenosis in diabetic porcine model
Previous preclinical studies of drug-eluting stents mainly
assessed their safety more than efficacy in the non-dia-
betic settings. In a non-diabetic porcine model, Suzuki et
al reported that SES reduced in-stent neointimal prolifer-
Micrographs of stented left anterior descending arteries in  diabetic (A) and control (B) porcine with HE staining (× 10  objective) Figure 1
Micrographs of stented left anterior descending arteries in 
diabetic (A) and control (B) porcine with HE staining (× 10 
objective).
Table 3: Angiographic and IVUS Follow-up Results
Diabetic group 
(n = 15)
Control group 
(n = 15)
In-stent MLD(mm) 2.45 ± 0.32* 2.82 ± 0.21
In-segment MLD(mm) 2.43 ± 0.29* 2.79 ± 0.27
In-stent DS(%) 40.4 ± 24.0* 20.2 ± 17.7
In-segment DS(%) 43.1 ± 23.9* 21.3 ± 15.7
In-stent LL(mm) 0.33 ± 0.19* 0.10 ± 0.09
In-segment LL(mm) 0.31 ± 0.18* 0.10 ± 0.15
In-stent restenosis > 50% 
(number of stent)
62
Neointimal volume(mm3) 21.9 ± 18.7** 3.87 ± 2.89
%IH 26.7 ± 19.2** 7.3 ± 6.1
IVUS = intravascular ultrasound, MLD = minimal lumen diameter, DS 
= diameter stenosis, LL = late loss, %IH = percentage of intimal 
hyperplasia. *p < 0.05, **p < 0.001 vs. control group.
Table 2: Angiographic and procedural features
Diabetic group 
(n = 15)
Control group 
(n = 15)
LAD 14 13
LCX 3 4
RCA 13 13
Reference vessel diameter (mm) 2.59 ± 0.32 2.71 ± 0.27
Stent deploy pressure(atm) 13.4 ± 3.0 14.5 ± 3.7
Final MLD(mm) 3.04 ± 0.30 3.18 ± 0.22
Stent to vessel ratio 1.11 ± 0.12 1.18 ± 0.05
LAD = left anterior descending artery, LCX = left circumflex artery, 
RCA = right coronary artery, MLD = minimal lumen diameter
Table 4: Results of histological analysis
Diabetic group 
(n = 15)
Control group 
(n = 15)
IS 1.68 ± 0.19 1.73 ± 0.13
Lumen area(mm2) 4.47 ± 2.56* 5.85 ± 2.07
Area within IEL(mm2) 6.19 ± 0.93 6.23 ± 1.01
Neointimal area(mm2) 1.59 ± 0.76 * 0.41 ± 0.18
MIT(mm) 1.24 ± 0.76* 0.59 ± 0.28
IS = injury score; IEL = internal elastic limina; EEL = external elastic 
lamina; MIT = maximal intima thickness. *p < 0.05**p < 0.001 vs 
control grpup.Cardiovascular Diabetology 2007, 6:16 http://www.cardiab.com/content/6/1/16
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ation at 28 days, compared to the bare metal stent [24]. As
drug-eluting stents have recently been widely applied to
majority of diabetic patients during percutaneous coro-
nary intervention in routine clinical practice, determina-
tion of the inhibitory effect of SES on neointimal growth
in a diabetic animal model may be more relevant to the
understanding of mechanism for an increased restenosis
rate seen in the clinical diabetic cohort, although neointi-
mal proliferation was supposed to be same as in bare-
metal stent studies[19]. While increased neointimal
hyperplasia was shown in the diabetic rat aorta after
implantation of drug-eluting stent [25], the changes of
coronary neointimal proliferation in large animal models
remain unclear.
In this study, we successfully established STZ-induced dia-
betic porcine model. Minipigs were chosen because their
coronary anatomy and vascular structure were thought to
be more ideal for stent implantation than other animal
models in the assessment of this device. In order to avoid
the influence of coronary distribution, two drug-eluting
stents have been deployed into two major epicardial cor-
onary arteries for each animal, and left anterior descend-
ing artery and right coronary artery were preferentially
stented, as restenosis was more common in these arteries
than in left circumflex artery [26,27]. The final stent-to-
vessel diameter ratio ranged 1.1~ 1.2:1 in the current
study, which could generally create sufficient coronary
injury to induce neointimal hyperplasia [28].
In general, neointimal response is exaggerated and the
time course of healing is more prolonged in humans than
in animals [29]. In a porcine model, peak neointimal
growth after implantation of bare metal stents is observed
at 28 days, compared with 6–12 months in humans
[19,30]. The precise time course of peak neointimal
growth in human coronary arteries after drug-eluting stent
implantation remains not fully defined. Previous animal
studies have shown favorable results of 28 days after drug-
eluting stent deployment, with a lack of sustained efficacy
at 3 and 9 months [24]. Previous studies have found that
the degree of neointimal hyperplasia peaked at 6 months
after intervention in the coronary arteries followed by
regression in some extent [30,31]. The findings at 6
months when the injury healing process is completed in
animals, may stand for the results of two to three years in
human [30]. Therefore, we assessed the 6-month angio-
graphic and IVUS results in the diabetic porcine after
receiving SES implantation. Our study indicates that in
TNF-α, IL-1 and IL-6 mRNA in aortic intima of diabetic por- cine and controls Figure 4
TNF-α, IL-1 and IL-6 mRNA in aortic intima of diabetic por-
cine and controls. # P < 0.05.
Uncorrected (%) and corrected (%IS) percentage of stenosis  between the two groups. * p < 0.05, IS = injury score Figure 2
Uncorrected (%) and corrected (%IS) percentage of stenosis 
between the two groups. * p < 0.05, IS = injury score.
Immunohistochemistry and Western blotting of TNF-α (×40  objective) Figure 3
Immunohistochemistry and Western blotting of TNF-α (×40 
objective). TNF-α expression in aortic intima tissue of dia-
betic (A) and control (B) porcine. C, TNF-α levels quantified 
in conditioned medium of aortic intima. *p < 0.001.Cardiovascular Diabetology 2007, 6:16 http://www.cardiab.com/content/6/1/16
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the diabetic animals, the degree of neointimal prolifera-
tion was significantly exaggerated than that in the control
group, with respect to increased in-stent late lumen loss at
angiography (0.33 ± 0.19 mm vs. 0.10 ± 0.09 mm, p <
0.05) and percentage of volume obstruction by IVUS
imaging (26.7% ± 19.2% vs. 7.3% ± 6.1%, p < 0.001) dur-
ing 6-month follow-up. The latter has been regarded as an
accurate index for evaluating the efficacy of neointimal
inhibition in drug-eluting stent era [32]. Furthermore, his-
tological findings after animal sacrifice were also consist-
ent with the angiographic and IVUS results. After
correction of the injury score, the percentage of lumen
area stenosis was significantly increased in diabetic group
(23.7% ± 17.4% vs. 11.9% ± 13.2% in control group, p <
0.05).
Mechanism of exaggerated vascular response in diabetic 
porcine
The mechanisms of neointimal hyperplasia after coronary
stenting with SES are complex, involving damage of vessel
medium, endothelial laceration, platelet aggregation and
activation, and release of tissue growth factors [30]. In dia-
betes, metabolic abnormalities and hemodynamic
changes may occur, including hyperglycemia, insulin-
resistance, hyperlipidemia, which may lead to hyperten-
sion, endothelial dysfunction, and atherosclerotic plaque
formation [33,34]. In addition, evidence is mounting that
an exaggerated inflammatory response within the blood
vessel wall contributes to acceleration of vascular lesion
area and complexity. The magnitude of vascular inflam-
matory response to injury after coronary stenting may
play a central role for the degree of neointimal prolifera-
tion and correlated with adverse late clinical outcomes
(death, myocardial infarction, recurrent ischemia, and
restenosis) [35]. Clinical studies in support of the anti-
inflammatory effects of abciximab and statins by modu-
lating atherosclerotic plaque stability have been reported
[5].
Our results strongly suggest that exaggerated neointimal
hyperplasia after SES implantation in the diabetic porcine
may be related to an enhanced inflammatory response to
vascular injury. In this study and our previous report with
less amount of diabetic animal models [18], a great eleva-
tion of mRNA levels of cytokine TNF-α, IL-1β and IL-6
and a dramatic increase of TNF-α secretion in the aortic
wall of diabetic porcine, as comparing to the non-diabetic
animals, may be caused by activation of inflammation-
related pathways and regulators in vessel wall driven by
hyperglycemia, oxidative stress and formation of
advanced glycated end products, further supporting the
concept that diabetes mellitus is an independent and
potent risk factor for atherosclerosis [6,36]. Pathophysio-
logical features detected in aorta properly represent gen-
eral phenomenon in large as well as medium size arteries
[34]. Nevertheless, it would be worthwhile to evaluate the
degree of inflammation in the non-stented branch of cor-
onary vasculatures as well. Our results indicate that
enhanced inflammatory response in diabetic cohort may
also have contributed to the development of neointimal
hyperplasia even after drug-eluting stent implantation,
although their precise relationship still needs further
investigation.
In this study, we examined the inflammatory mediators in
the aortic intima to exclude the interference from poly-
mer-induced inflammation in the coronary arteries. The
non-reabsorbable polymer loaded on the drug-eluting
stents would cause local chronic inflammation and lead
to increased neointimal hyperplasia and late stent throm-
bosis [35]. As vascular inflammation represents the "final
common pathway" for many disease processes, it may,
thus, represent the "ultimate therapeutic target" for phar-
macologic inhibition. In this context, emphasis should be
made with regard to the use of anti-inflammatory agents
in the prevention of neointimal hyperplasia after implan-
tation of SES in clinical practice.
Limitations
Although animal model of restenosis has been widely
used to evaluate the safety and efficacy of coronary stents,
the accuracy of reflecting the human coronary artery
response to such stents is still unclear. STZ was used to
induce diabetes in the current study, which results in a
type 1 diabetic model with injury of pancreas; therefore,
the term from induction of diabetes to stent implantation
is limited in this study. It has recently been demonstrated
that patients with insulin-dependent diabetes had higher
in-stent late lumen loss compared to non-insulin depend-
ent diabetic patients. Hyperinsulinemia was reported to
enhance neointimal hyperplasia in the rat carotid injury
model through activation of ras/MARK pathway [37], but
in a human study, insulin levels showed no significant
association with restenosis [38]. Likewise, only male ani-
mals were used, therefore, gender-related differences in
the rate of restenosis in diabetic state or in the use of SES
remain unclear. Furthermore, inflammatory cytokines
were measured using conditioned media of the aortic
intima, it would be interesting to evaluate serum levels of
these inflammatory markers, which could monitor the
time course of the inflammatory activity in this experi-
mental model. Finally, results from animal studies may
not translate to patients, due to improper or biased varia-
ble selection, or confounding effects of vascular injury
[19].
Conclusion
Neointimal hyperplasia persisted at 6 months after SES
implantation in the diabetic porcine model, which may
be, at least partly, related to an exacerbated inflammatory
response within the diabetic blood vessel wall. Further
studies are needed to assess the molecular mechanism ofCardiovascular Diabetology 2007, 6:16 http://www.cardiab.com/content/6/1/16
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enhanced neointimal proliferation and effects of pharma-
cological intervention.
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